Grail

American biotechnology and pharmaceutical company

GRAL Nasdaq ISIN US3847471014 SEC CIK 1699031
Follow Grail Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $37.5M +3.7% vs same quarter last year
Net income −$103.6M −16.4% vs same quarter last year
EPS, diluted −$2.21 +10.2% vs same quarter last year
Operating cash flow −$74.7M −18.2% vs same quarter last year
Revenue by quarter
$38.3M
$31.8M
$35.5M
$36.2M
$43.6M
$40.8M
$44.7M
$37.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$6B−$4B−$2B$0$2BFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$147.2M−$408.4M
FY24$125.6M−$2B
FY23$93.1M−$1.5B
FY22$55.6M−$5.4B
MarginsShare of revenue
  • Operating margin
  • Net margin
−10000%−7500%−5000%−2500%0%FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−382%−277.5%
FY24−1743%−1613.9%
FY23−1627.6%−1574.2%
FY22−9798.2%−9719.3%
Free cash flowOperating cash flow minus capital expenditure
−$800M−$600M−$400M−$200M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$299.9M
FY24−$582.4M
FY23−$608.7M
FY22−$584.2M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Grail
  • Healthcare median
−10000%−7500%−5000%−2500%0%FY22FY23FY24FY25
Show the numbers
YearGrailHealthcare median
FY25−277.5%−30.6%
FY24−1613.9%−47%
FY23−1574.2%−58%
FY22−9719.3%−80.4%